bivalirudin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
hirudin derivatives 385 128270-60-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bivalirudin
  • angiomax
  • angiox
  • hirulog
designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition
  • Molecular weight: 2180.32
  • Formula: C98H138N24O33
  • CLOGP:
  • LIPINSKI: 3
  • HAC: 57
  • HDO: 28
  • TPSA: 901.57
  • ALOGS: -4.67
  • ROTB: 66

Drug dosage:

DoseUnitRoute
0.25 g P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 2000 FDA MEDICINES CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Heparin-induced thrombocytopenia 136.43 68.94 25 658 5287 90622477
Thrombosis in device 115.53 68.94 20 663 3055 90624709
Vascular stent thrombosis 90.00 68.94 14 669 1102 90626662
Drug ineffective 82.46 68.94 73 610 1384225 89243539
Coronary artery thrombosis 82.30 68.94 13 670 1129 90626635

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombosis in device 176.14 61.37 35 1123 3111 42617066
Heparin-induced thrombocytopenia 166.36 61.37 38 1120 6559 42613618
Vascular stent thrombosis 139.56 61.37 29 1129 3213 42616964
Drug ineffective 106.02 61.37 105 1053 630092 41990085
Coronary artery thrombosis 101.54 61.37 21 1137 2265 42617912
Coagulation time abnormal 95.52 61.37 13 1145 101 42620076
Kounis syndrome 66.82 61.37 16 1142 3352 42616825
Acute myocardial infarction 66.24 61.37 32 1126 58133 42562044
Oesophageal ulcer haemorrhage 65.66 61.37 11 1147 372 42619805

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Heparin-induced thrombocytopenia 274.60 60.50 58 1792 11366 110576083
Thrombosis in device 223.29 60.50 43 1807 5284 110582165
Vascular stent thrombosis 221.04 60.50 41 1809 4120 110583329
Drug ineffective 157.16 60.50 156 1694 1520384 109067065
Coronary artery thrombosis 140.91 60.50 27 1823 3217 110584232
Coagulation time abnormal 111.26 60.50 15 1835 184 110587265
Acute myocardial infarction 95.86 60.50 40 1810 83737 110503712
Haemorrhage 80.36 60.50 38 1812 106654 110480795
Thrombosis 79.69 60.50 38 1812 108624 110478825
Cardiac tamponade 64.28 60.50 18 1832 11289 110576160
Pharyngeal haemorrhage 62.87 60.50 12 1838 1395 110586054
Oesophageal ulcer haemorrhage 60.96 60.50 11 1839 941 110586508

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AE06 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Direct thrombin inhibitors
FDA MoA N0000009963 Thrombin Inhibitors
FDA EPC N0000175518 Direct Thrombin Inhibitor
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
FDA EPC N0000175980 Anti-coagulant
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:65232 EC 3.4.21.5 (thrombin) inhibitor

Related Drugs by ATC class:

B01AE Direct thrombin inhibitors 5 drugs
argatrobandabigatran etexilatedesirudinlepirudinximelagatran

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Percutaneous coronary intervention indication 415070008
Unstable Angina Pectoris during PTCA indication
Acute coronary syndrome off-label use 394659003
Intracranial hemorrhage contraindication 1386000
Bleeding contraindication 131148009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.06 acidic
pKa2 3.51 acidic
pKa3 3.89 acidic
pKa4 4.04 acidic
pKa5 4.21 acidic
pKa6 4.49 acidic
pKa7 9.65 acidic
pKa8 11.93 acidic
pKa9 12.59 acidic
pKa10 12.84 acidic
pKa11 13.06 acidic
pKa12 13.08 acidic
pKa13 13.4 acidic
pKa14 13.64 acidic
pKa15 13.69 acidic
pKa16 13.81 acidic
pKa17 13.99 acidic
pKa18 10.75 Basic
pKa19 8.16 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
250MG/50ML (5MG/ML) ANGIOMAX RTU MAIA PHARMS INC N211215 July 25, 2019 RX SOLUTION INTRAVENOUS 11903993 May 20, 2039 USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
250MG/50ML (5MG/ML) ANGIOMAX RTU MAIA PHARMS INC N211215 July 25, 2019 RX SOLUTION INTRAVENOUS 11918622 May 20, 2039 USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
250MG/50ML (5MG/ML) ANGIOMAX RTU MAIA PHARMS INC N211215 July 25, 2019 RX SOLUTION INTRAVENOUS 12472224 May 20, 2039 USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prothrombin Enzyme INHIBITOR Ki 8.60 IUPHAR CHEMBL

External reference:

IDSource
4021268 VUID
N0000148708 NUI
D03136 KEGG_DRUG
285044 RXNORM
C0168273 UMLSCUI
CHEBI:59173 CHEBI
CHEMBL5314348 ChEMBL_ID
CHEMBL5314353 ChEMBL_ID
DB00006 DRUGBANK_ID
C074619 MESH_SUPPLEMENTAL_RECORD_UI
6470 IUPHAR_LIGAND_ID
7282 INN_ID
TN9BEX005G UNII
16129704 PUBCHEM_CID
15879 MMSL
234768 MMSL
41019 MMSL
d04744 MMSL
129498009 SNOMEDCT_US
400610005 SNOMEDCT_US
4021268 VANDF
009031 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 16729-275 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 42023-622 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 52958-034 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 23 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 55111-652 INJECTION 250 mg INTRACAVERNOUS ANDA 25 sections
BIVALIRUDIN Human Prescription Drug Label 1 55150-210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 63323-562 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 27 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 63323-562 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 27 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 67457-256 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70436-025 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 250 mg INTRAVENOUS ANDA 26 sections
Bivalirudin Human Prescription Drug Label 1 70511-142 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 25 sections
BIVALIRUDIN HUMAN PRESCRIPTION DRUG LABEL 1 71288-427 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
BIVALIRUDIN HUMAN PRESCRIPTION DRUG LABEL 1 71288-427 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 72572-035 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 83634-400 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections